SCI Pharmtech Inc
TWSE:4119
SCI Pharmtech Inc
Net Income
SCI Pharmtech Inc
Net Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Net Income
NT$646.9m
|
CAGR 3-Years
115%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
7%
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Net Income
NT$1.5B
|
CAGR 3-Years
16%
|
CAGR 5-Years
11%
|
CAGR 10-Years
5%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Net Income
NT$198.2m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-4%
|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Net Income
NT$413m
|
CAGR 3-Years
11%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-4%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Net Income
NT$6.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Net Income
NT$1.6B
|
CAGR 3-Years
17%
|
CAGR 5-Years
23%
|
CAGR 10-Years
14%
|
|
SCI Pharmtech Inc
Glance View
SCI Pharmtech Corp. is engaged in the biotechnology and medical care industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2002-08-12. The firm's main products include APIs, API intermediates and special and precision chemicals. The firm distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
See Also
What is SCI Pharmtech Inc's Net Income?
Net Income
646.9m
TWD
Based on the financial report for Dec 31, 2024, SCI Pharmtech Inc's Net Income amounts to 646.9m TWD.
What is SCI Pharmtech Inc's Net Income growth rate?
Net Income CAGR 10Y
7%
Over the last year, the Net Income growth was 78%. The average annual Net Income growth rates for SCI Pharmtech Inc have been 115% over the past three years , -2% over the past five years , and 7% over the past ten years .
You don't have any saved screeners yet